Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway

REFERENCES

• Tan W, Lu J, Huang M, Li YB, Chen MW, Wu GS, et al.. Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med. 2011;6:27.
   PubMed Web of Science ®Google Scholar
• Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004;27:1769–74.
   PubMed Web of Science ®Google Scholar
• Li QL, Cheng H, Zhu GQ, Yang L, Zhou A, Wang X, et al.. Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting. Biol Pharm Bull. 2010;33:415–20.
   PubMed Web of Science ®Google Scholar
• Xie H, Qin YX, Zhou YL, Tong LJ, Lin LP, Geng MY, et al.. GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms. Acta Pharmacol Sin. 2009;30:346–54.
   PubMed Web of Science ®Google Scholar
• Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res. 2003;48:231–6.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med. 1971;285:1182–6.
   PubMed Web of Science ®Google Scholar
• D’Amore PA, Thompson RW. Mechanisms of angiogenesis. Annu Rev Physiol. 1987;49:453–64.
   PubMed Web of Science ®Google Scholar
• Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol. 2011;81:1183–91.
   PubMed Web of Science ®Google Scholar
• Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets. 2011;11:624–53.
   PubMed Web of Science ®Google Scholar
• Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, et al.. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008;68:1843–50.
   PubMed Web of Science ®Google Scholar
• Aepfelbacher M, Essler M, Huber E, Sugai M, Weber PC. Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1623–9.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, et al.. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res. 2011;17:4439–50.
   PubMed Web of Science ®Google Scholar
• Ma L, Chen J, Wang X, Liang X, Luo Y, Zhu W, et al.. Structural modification of honokiol, a biphenyl occurring in Magnolia officinalis: the evaluation of honokiol analogues as inhibitors of angiogenesis and for their cytotoxicity and structure-activity relationship. J Med Chem. 2011;54:6469–81.
   PubMed Web of Science ®Google Scholar
• Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al.. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.
   PubMed Web of Science ®Google Scholar
• Liu MY, Pang XF, Yi TF, Cho SG, Qu W, Pinkaew D, et al.. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting Rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res. 2009;69:518–25.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl). 2003;81:20–31.
   PubMed Web of Science ®Google Scholar
• Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, et al.. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem. 2000;275:10661–72.
   PubMed Web of Science ®Google Scholar
• Soga N, Namba N, McAllister S, Cornelius L, Teitelbaum SL, Dowdy SF, et al.. Rho family GTPases regulate VEGF-stimulated endothelial cell motility. Exp Cell Res. 2001;269:73–87.
   PubMed Web of Science ®Google Scholar
• Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, et al.. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol. 2008;75:1083–92.
   PubMed Web of Science ®Google Scholar
• Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res. 2007;67:6899–906.
   PubMed Web of Science ®Google Scholar
• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5:203–20.
   PubMed Web of Science ®Google Scholar
• Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:33–7.
   PubMed Web of Science ®Google Scholar
• Hong SY, Kwak KW, Ryu CK, Kang SJ, Chung KH. Antiproliferative effects of 6-anilino-5-chloro-1H-benzo[d]imidazole-4,7-dione in vascular smooth muscle cells. Bioorg Med Chem. 2008;16:644–9.
   PubMed Web of Science ®Google Scholar
• Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem. 1998;273:4027–34.
   PubMed Web of Science ®Google Scholar
• Alblas J, Slager-Davidov R, Steenbergh PH, Sussenbach JS, van der Burg B. The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene. 1998;16:131–9.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, et al.. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today. 2011;16:219–28.
   PubMed Web of Science ®Google Scholar
• Kozma R, Ahmed S, Best A, Lim L. The Ras-related protein Cdc42hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3t3 fibroblasts. Mol Cell Biol. 1995;15:1942–52.
   PubMed Web of Science ®Google Scholar
• Swart-Mataraza JM, Li ZG, Sacks DB. IQGAP1 is a component of Cdc42 signaling to the cytoskeleton. J Biol Chem. 2002;277:24753–63.
   PubMed Web of Science ®Google Scholar
• Kholmanskikh SS, Koeller HB, Wynshaw-Boris A, Gomez T, Letourneau PC, Ross ME. Calcium-dependent interaction of Lis1 with IQGAP1 and Cdc42 promotes neuronal motility. Nat Neurosci. 2006;9:50–7.
   PubMed Web of Science ®Google Scholar